Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 3/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TTK | P33981 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | HTR5A | P47898 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886586 | 0.97 | NPSR1 (0.58) | ATMNPSR1KDM4EALDH1A1NPC1 | |
| SCHEMBL2880879 | 0.89 | ATM (0.45) | ATMNPSR1KDM4EALDH1A1NPC1 | |
| SCHEMBL2883740 | 0.87 | NPSR1 (0.46) | ATMNPSR1KDM4EALDH1A1NPC1 | |
| SCHEMBL2887042 | 0.85 | DYRK1A (0.63) | KDM4EALDH1A1NPC1RAB9AGSK3A | |
| SCHEMBL2886287 | 0.84 | IDO1 (0.59) | ATMNPSR1HPGDIDO1TTK | |
| SCHEMBL2889514 | 0.78 | GSK3A (0.58) | ATMNPSR1KDM4EALDH1A1NPC1 | |
| SCHEMBL2884573 | 0.78 | GSK3A (0.55) | ATMNPSR1KDM4EALDH1A1NPC1 | |
| SCHEMBL2886307 | 0.78 | LRRK2 (0.56) | KDM4EALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL7698750 | 0.77 | ALDH1A1 (0.61) | ATMNPSR1KDM4EALDH1A1NPC1 | |
| SCHEMBL2879931 | 0.75 | DYRK1A (0.78) | NPSR1KDM4EALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035429-B1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON INC (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2035429-B1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON INC (US) | 2012-09-19 | — | — | EP | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007149557-A1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CDK5, CDK5R1, CDK7 | ATM 1480/4885NPSR1 3523/4885KDM4E 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.